(Q35978475)

11 August 2017

Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients (English)

1 reference

11 August 2017

Tartour E

1

1 reference

11 August 2017

Dorval T

2

1 reference

11 August 2017

Mosseri V

3

1 reference

11 August 2017

Deneux L

4

1 reference

11 August 2017

Mathiot C

5

1 reference

11 August 2017

Brailly H

6

1 reference

11 August 2017

Montero F

7

1 reference

11 August 2017

Joyeux I

8

1 reference

11 August 2017

Pouillart P

9

1 reference

11 August 2017

Fridman WH

10

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 May 1994

1 reference

British Journal of Cancer

11 August 2017

1 reference

11 August 2017

69

1 reference

11 August 2017

5

1 reference

11 August 2017

911-913

1 reference

Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968905

Antitumor activity of recombinant interleukin 6 in mice

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968905

Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968905

Interleukin 2 therapy in cancer: identification of responders

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968905

Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968905

IFN-beta 2/IL-6 augments the activity of human natural killer cells

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968905

IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968905

Prognosis after initial recurrence of cutaneous melanoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968905

Pathologic concentrations of interleukin 6 inhibit T cell responses via induction of activation of TGF-beta.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968905

HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968905

Is the AIDS virus responsible for the disease?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968905

Interleukin-6 production by human melanoma cell lines

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968905

Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1968905

24 September 2018

1 reference

12 December 2020

Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells

1 reference

PubMed

12 December 2020

A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III)

1 reference

PubMed

12 December 2020

Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas

1 reference

PubMed

12 December 2020

Identifiers

DOI

10.1038/BJC.1994.175

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

8180022

1 reference